logo
  

Brazil Central Bank Keeps Rate Unchanged, Hints At More Rate Hikes

Brazil central bank kept its key interest rate unchanged for the third straight meeting on Wednesday and hinted at tightening further if inflation fails to slow as expected.

The monetary policy committee, known as Copom, decided to hold the Selic rate at 13.75 percent. This was the highest rate since late 2016.

The bank had raised its key rate from a record low 2.00 percent in March 2021 to its current level.

The Committee underscored that future monetary policy steps can be adjusted and will not hesitate to resume the tightening cycle if the disinflationary process does not proceed as expected.

Policymakers observed upside risks to inflation from the country's future fiscal framework and additional fiscal stimuli that underpins demand. President-elect Luiz Inacio Lula da Silva is set to take office on January 1.

"The Committee will closely monitor future developments in fiscal policy and, in particular, its effects on asset prices and inflation expectations, with potential impacts on the dynamics of future inflation," the bank said in the statement.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Health insurer Humana Inc. reported Wednesday a net loss for the fourth quarter that slightly widened from last year, hurt primarily by charges associated with productivity initiatives, despite 6.6 percent revenue growth. Adjusted earnings for the quarter topped analysts' expectations, while quarterly revenues missed it by a whisker. South Plainfield, New Jersey-based Two Rivers Coffee is recalling its peanut butter single serve hot chocolate pods citing an undeclared peanut allergen, the U.S. Food Drug Administration said. The recall involves peanut butter single serve hot chocolate pods distributed as "Brooklyn Bean Peanut Butter Cup Hot Cocoa", "Pingo Peanut Butter Cookie Hot Chocolate" and ... Shares of Novartis AG were losing around 2 percent in the early morning trading in Switzerland after the drug major reported Wednesday sharply lower profit in its fourth quarter with weak sales as well as the absence of prior year's hefty Roche income. Adjusted earnings, however, topped market estimates, while top line missed their view. Further, the company announced higher dividend...
Follow RTT